Brief: Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
20/10/2025 13:46
Oct 20 (Reuters) - Palisade Bio Inc PALI.O: PALISADE BIO ANNOUNCES FIRST PATIENTS DOSED IN PHASE 1B STUDY OF ORAL FIRST-IN-CLASS PDE4 INHIBITOR PRODRUG, PALI-2108, FOR THE TREATMENT OF FIBROSTENOTIC CROHN’S DISEASE (FSCD) PALISADE BIO INC - TOPLINE DATA FOR PALI-2108 STUDY EXPECTED IN Q1 2026 PALISADE BIO INC - DATA TO SUPPORT PHASE 2 IND SUBMISSIONS TO FDA IN H1 2026 Source text: ID:nGNX7gM0BX Further company coverage: PALI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing